IP Library Granted Patent US 9,770,429
Granted Patent B2
US 9,770,429 · App. 15/380,146 · Granted Sep 26, 2017

4-methylsulfonyl-2-butenenitrile and its pharmaceutical use

Inventors: Joseph P. St. Laurent (Lakeville, MA); Gerald S. Jones (Norwood, MA); David M. Bresse (Middleboro, MA); Scott A. Goodrich (Stoughton, MA)
Assignee: OLATEC THERAPEUTICS LLC
A61K31/275A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,770,429
App. No.
15/380,146
Granted
Sep 26, 2017
Kind
B2
Abstract

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 4-methylsulfonyl-2-butenenitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred routes of administration.

Claims (7)

1. A method of treating inflammation or pain, comprising the steps of:

administering to a subject suffering from inflammation or pain 4-methylsulfonyl-2-butenenitrile or a pharmaceutically acceptable salt thereof, in an amount effective to treat inflammation or pain.

2. The method according to claim 1 , wherein said method reduces or alleviates the symptoms of localized manifestations of inflammation characterized by acute or chronic swelling, pain, or redness.

3. The method according to claim 1 , wherein said compound is administered by topical administration or oral administration.

4. The method according to claim 1 , wherein said inflammation and/or pain is associated with a skeletal or muscular disease or condition selected from the group consisting of: musculoskeletal sprains, musculoskeletal strains, tendonopathy, peripheral radiculopathy, osteoarthritis, degenerative joint disease, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, system lupus erythematosus, costochondritis, tendonitis, bursitis, temporomandibular joint syndrome, and fibromyalgia.

5. The method according to claim 1 , wherein said inflammation and/or pain is associated with joints, ligaments, tendons, bone, muscles, or fascia.

6. The method according to claim 1 , wherein said inflammation and/or pain is associated with an inflammatory skin disease or disorder of dermatitis or psoriasis.

Assignments (2)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
CHANGE OF NAME Recorded Aug 29, 2017
From: OLATEC INDUSTRIES LLC
To: OLATEC THERAPEUTICS LLC
Reel/Frame 043708/0862 →
Continuity (5)
Division 15084816 · Mar 30, 2016
Continuation In Part PCTUS2014058685 · Oct 1, 2014
Provisional Application 61887776 · Oct 7, 2013
Provisional Application 62142855 · Apr 3, 2015
Related Publication 20170231944A1 · Aug 17, 2017